FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124336661> ?p ?o ?g. }

• W3124336661 endingPage "e2032053" @default.
• W3124336661 startingPage "e2032053" @default.
• W3124336661 abstract "<h3>Importance</h3> Understanding Black vs White differences in pharmacotherapy efficacy and the underlying reasons is critically important to reducing tobacco-related health disparities. <h3>Objective</h3> To compare pharmacotherapy efficacy and examine variables to explain Black vs White differences in smoking abstinence. <h3>Design, Setting, and Participants</h3> This study is a secondary analysis of the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) double-blind, placebo-controlled, randomized clinical trial, which took place at clinical trial centers, academic centers, and outpatient clinics in 29 states in the US. US Black and White smokers who smoked 10 or more cigarettes per day with and without psychiatric comorbidity were enrolled between November 2011 and January 2015. Data analysis was performed from July 2019 to January 2020. <h3>Interventions</h3> Participants were randomized (1:1:1:1) in a double-blind, triple-dummy, placebo- and active-controlled (nicotine patch) trial of varenicline and bupropion for 12 weeks with follow-up through week 24. <h3>Main Outcomes and Measures</h3> Biochemically verified continuous cigarette abstinence rate (CAR) from weeks 9 to 24. Baseline, postbaseline treatment, and safety characteristics were examined as variables to explain race differences in abstinence. <h3>Results</h3> Of the 1065 Black smokers enrolled, 255 were randomized to receive varenicline, 259 received bupropion, 286 received nicotine replacement therapy (NRT [ie, nicotine patch]), and 265 received placebo. Among the 3044 White smokers enrolled, 778 were randomized to receive varenicline, 769 received bupropion, 738 received NRT, and 759 received placebo. Participants were predominantly female (614 Black [57.7%] and 1786 White [58.7%] women) and heavy smokers (mean [SD] cigarettes per day, 18.2 [7.9] for Black and 20.0 [7.5] for White smokers), with a mean (SD) age of 47.2 (11.2) years for Black and 46.5 (12.7) years for White participants. Treatment and race were associated with CAR for weeks 9 to 24. The CAR was 4.9% lower for Black vs White participants (odds ratio [OR], 0.53; 95% CI, 0.41-0.69;<i>P</i> < .001); differences were found across all treatments. Pooling psychiatric and nonpsychiatric cohorts, varenicline (OR, 2.63; 95% CI, 1.90-3.63;<i>P</i> < .001), bupropion (OR, 1.75; 95% CI, 1.25-2.46;<i>P</i> = .001), and NRT (OR, 1.52; 95% CI, 1.07-2.16;<i>P</i> = .02) had greater efficacy than placebo for White participants. Only varenicline (OR, 2.63; 95% CI, 1.26-5.48;<i>P</i> = .01) had greater efficacy than placebo for Black participants. Baseline, postbaseline, and safety characteristics differed by race, but these variables did not eliminate the association of race with CAR. Black participants had 49% reduced odds of CAR for weeks 9 to 24 compared with White participants in the adjusted model (OR, 0.51; 95% CI, 0.39-0.66;<i>P</i> < .001). <h3>Conclusions and Relevance</h3> Black and White smokers achieved the highest rate of abstinence while taking varenicline, suggesting that it is the best first-line therapy for these groups. However, Black smokers were less responsive to all therapies, including placebo. Understanding variables (eg, socioeconomic or biological) beyond those may lead to improved treatment outcomes for Black smokers. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01456936" @default.
• W3124336661 created "2021-02-01" @default.
• W3124336661 creator A5005233809 @default.
• W3124336661 creator A5044839643 @default.
• W3124336661 creator A5048294207 @default.
• W3124336661 creator A5060331544 @default.
• W3124336661 creator A5073662032 @default.
• W3124336661 creator A5076851072 @default.
• W3124336661 creator A5083971769 @default.
• W3124336661 date "2021-01-19" @default.
• W3124336661 modified "2023-10-12" @default.
• W3124336661 title "Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation" @default.
• W3124336661 cites W111152427 @default.
• W3124336661 cites W1540070140 @default.
• W3124336661 cites W1640685893 @default.
• W3124336661 cites W1666503981 @default.
• W3124336661 cites W1886575675 @default.
• W3124336661 cites W1966407313 @default.
• W3124336661 cites W1970461091 @default.
• W3124336661 cites W1972143523 @default.
• W3124336661 cites W1974317576 @default.
• W3124336661 cites W1975258778 @default.
• W3124336661 cites W1979158851 @default.
• W3124336661 cites W1980076481 @default.
• W3124336661 cites W1984116490 @default.
• W3124336661 cites W1985523783 @default.
• W3124336661 cites W1986773132 @default.
• W3124336661 cites W1988367512 @default.
• W3124336661 cites W1994473494 @default.
• W3124336661 cites W1999673711 @default.
• W3124336661 cites W2004652347 @default.
• W3124336661 cites W2007006847 @default.
• W3124336661 cites W2016263931 @default.
• W3124336661 cites W2016545633 @default.
• W3124336661 cites W2019367499 @default.
• W3124336661 cites W2021089766 @default.
• W3124336661 cites W2029781096 @default.
• W3124336661 cites W2038300528 @default.
• W3124336661 cites W2038528685 @default.
• W3124336661 cites W2042349958 @default.
• W3124336661 cites W2053240677 @default.
• W3124336661 cites W2055705126 @default.
• W3124336661 cites W2056795229 @default.
• W3124336661 cites W2057743790 @default.
• W3124336661 cites W2066618117 @default.
• W3124336661 cites W2073382458 @default.
• W3124336661 cites W2073988837 @default.
• W3124336661 cites W2075713006 @default.
• W3124336661 cites W2079952628 @default.
• W3124336661 cites W2086925668 @default.
• W3124336661 cites W2087551961 @default.
• W3124336661 cites W2101566038 @default.
• W3124336661 cites W2102822714 @default.
• W3124336661 cites W2104300284 @default.
• W3124336661 cites W2105254196 @default.
• W3124336661 cites W2116257115 @default.
• W3124336661 cites W2128703663 @default.
• W3124336661 cites W2129732746 @default.
• W3124336661 cites W2141348739 @default.
• W3124336661 cites W2148083007 @default.
• W3124336661 cites W2150595483 @default.
• W3124336661 cites W2153803359 @default.
• W3124336661 cites W2160546717 @default.
• W3124336661 cites W2165643775 @default.
• W3124336661 cites W2166328543 @default.
• W3124336661 cites W2173504734 @default.
• W3124336661 cites W2271005668 @default.
• W3124336661 cites W2340896985 @default.
• W3124336661 cites W2389469497 @default.
• W3124336661 cites W2401562667 @default.
• W3124336661 cites W2569987730 @default.
• W3124336661 cites W2611361473 @default.
• W3124336661 cites W2774916026 @default.
• W3124336661 cites W2909438155 @default.
• W3124336661 cites W2937959913 @default.
• W3124336661 cites W2955525647 @default.
• W3124336661 cites W4213393536 @default.
• W3124336661 cites W4230763453 @default.
• W3124336661 cites W4231177280 @default.
• W3124336661 cites W4231472360 @default.
• W3124336661 cites W4234092643 @default.
• W3124336661 cites W4243097204 @default.
• W3124336661 cites W4245078684 @default.
• W3124336661 cites W4247178142 @default.
• W3124336661 cites W4248967693 @default.
• W3124336661 cites W4249652232 @default.
• W3124336661 cites W4250413303 @default.
• W3124336661 cites W4251638237 @default.
• W3124336661 cites W4254705423 @default.
• W3124336661 cites W4255518842 @default.
• W3124336661 cites W4292810003 @default.
• W3124336661 doi "https://doi.org/10.1001/jamanetworkopen.2020.32053" @default.
• W3124336661 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7816102" @default.
• W3124336661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33464316" @default.
• W3124336661 hasPublicationYear "2021" @default.
• W3124336661 type Work @default.
• W3124336661 sameAs 3124336661 @default.
• W3124336661 citedByCount "21" @default.

• next